SPECIAL SEMINAR - Dr Jean-Luc COLL - Research Director - IAB Institute - GRENOBLE
"Nanomedicine and theranostics approaches in oncology"
200
Nanomedicine and theranostics approaches in oncology
Dr Jean-Luc COLL
Director of Research at INSERM
Team Leader
Institute for Advanced Biosciences Grenoble
Abstract
Our group is defining theranostic nanoparticles (NP). As such, our NP are used for diagnostic and therapeutic approaches in oncology. We are using a variety of materials, including metals, polymers and lipids, and we formulate them with different types of drugs and/or photoactive compounds.
They can then be used and tested in animal models as contrast agents to precisely detect and delineate the region to treat using MRI, X-rays, Near-Infrared light or ultrasounds and, in addition, our NP can be remotely activated on site using non-ionizing and/or ionizing radiations to specifically deliver combined synergistic therapeutic activities to the target tumor cells and their microenvironment, allowing for more effective treatments with fewer side effects.
These nanosystems can also be used intraoperatively for optical guided surgery of cancer.
